{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,14]],"date-time":"2026-11-14T11:22:08Z","timestamp":1794655328524,"version":"4.9.1"},"reference-count":38,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"5","license":[{"start":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T00:00:00Z","timestamp":1701907200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>We evaluated 58 patients with relapsed or refractory (r\/r) acute B-lymphoblastic leukemia (B-ALL; median age 42.5 years; range, 16-69 years), treated with inotuzumab ozogamicin (INO) between 2016-2022 and who received an allogeneic hematopoietic stem cell transplantation (allo-HCT) consecutively. Forty-seven (81%) of the 58 patients were heavily pretreated receiving intensive chemotherapy +\/- tyrosine kinase inhibitor, blinatumomab in 24 (41%) and allo-HCT at first-line in 11 (19%) patients. Complete remission rate prior to allo-HCT was 84%. Median follow-up was 30.5 months and median overall survival (OS) measured from start of INO was 11.2 months. One- and 2-year OS rates were 50% (95% confidence interval [CI]: 38.4-56.1) and 36.7% (95% CI: 25.5-52.9), respectively. Sinusoidal obstruction syndrome\/venous occlusive disease (SOS\/ VOD) after allo-HCT occurred in 17 (29%) patients. Of those, nine (53%) patients died due to SOS\/VOD and multi-organ failure. Two had received &gt;2 INO cycles (3 cycles, 5 cycles, N=1, each), all others \u22642 INO cycles prior to allo-HCT. Logistic regression analysis revealed conditioning with double alkylators (P=0.038) and allo-HCT during first-line therapy (P=0.050) as significant risk factors for SOS\/VOD and in trend allo-HCT \u226460 days from last INO application (P=0.07), whereas number of INO cycles before allo-HCT and time between last INO application and allo-HCT were not significant. Relapse\/progressive disease occurred in 20 (34%) patients. Of those, five (25%) patients are still alive, whereas 15 succumbed of their disease. Treatment with INO seems to be an effective approach with successful bridge-to-transplant. However, risk of SOS\/VOD is high, necessitating continuous monitoring and recognition of SOS\/VOD risk factors.<\/jats:p>","DOI":"10.3324\/haematol.2023.284310","type":"journal-article","created":{"date-parts":[[2023,12,7]],"date-time":"2023-12-07T03:21:24Z","timestamp":1701919284000},"page":"1385-1392","source":"Crossref","is-referenced-by-count":17,"title":["Impact of inotuzumab ozogamicin on outcome in relapsed or refractory acute B-cell lymphoblastic leukemia patients prior to allogeneic hematopoietic stem cell transplantation and risk of sinusoidal obstruction syndrome\/venous occlusive disease"],"prefix":"10.3324","volume":"109","author":[{"given":"Sabine","family":"Kayser","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Sartor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabio","family":"Giglio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Bruno","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jonathan","family":"Webster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Patrizia","family":"Chiusolo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Saraceni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selene","family":"Guerzoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Pochintesta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erika","family":"Borlenghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giovanni","family":"Marconi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Irene","family":"Zacheo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cerrano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prassede","family":"Salutari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Restuccia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariachiara","family":"Abbenante","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark J.","family":"Levis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard F.","family":"Schlenk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cristina","family":"Papayannidis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,12,7]]},"reference":[{"key":"60336","doi-asserted-by":"crossref","unstructured":"Hoelzer D, Bassan R, Dombret H. Acute lymphoblastic leukaemia in adult patients: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(Suppl 5):v69-82.","DOI":"10.1093\/annonc\/mdw025"},{"key":"60337","doi-asserted-by":"crossref","unstructured":"Spinelli O, Peruta B, Tosi M. Clearance of minimal residual disease after allogeneic stem cell transplantation and the prediction of the clinical outcome of adult patients with high-risk acute lymphoblastic leukemia. Haematologica. 2007; 92(5):612-618.","DOI":"10.3324\/haematol.10965"},{"key":"60338","doi-asserted-by":"crossref","unstructured":"Schrappe M. Detection and management of minimal residual disease in acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program. 2014; 2014(1):244-249.","DOI":"10.1182\/asheducation-2014.1.244"},{"key":"60339","doi-asserted-by":"crossref","unstructured":"Davila ML, Riviere I, Wang X. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med. 2014; 6(224):224.","DOI":"10.1126\/scitranslmed.3008226"},{"key":"60340","doi-asserted-by":"crossref","unstructured":"Cruz CR, Micklethwaite KP, Savoldo B. Infusion of donor-derived CD19-redirected virus-specific T cells for B-cell malignancies relapsed after allogeneic stem cell transplant: a phase 1 study. Blood. 2013; 122(17):2965-2973.","DOI":"10.1182\/blood-2013-06-506741"},{"key":"60341","doi-asserted-by":"crossref","unstructured":"Jacoby E. The role of allogeneic HHCT after CAR T cells for acute lymphoblastic leukemia. Bone Marrow Transplant. 2019; 54(Suppl 2):810-814.","DOI":"10.1038\/s41409-019-0604-3"},{"key":"60342","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, Thomas D, Ravandi F. Defining the course and prognosis of adults with acute lymphocytic leukemia in first salvage after induction failure or short first remission duration. Cancer. 2010; 116(24):5568-5574.","DOI":"10.1002\/cncr.25354"},{"key":"60343","doi-asserted-by":"crossref","unstructured":"Thomas DA, Kantarjian H, Smith TL. Primary refractory and relapsed adult acute lymphoblastic leukemia: characteristics, treatment results, and prognosis with salvage therapy. Cancer. 1999; 86(7):1216-1230.","DOI":"10.1002\/(SICI)1097-0142(19991001)86:7<1216::AID-CNCR17>3.0.CO;2-O"},{"key":"60344","doi-asserted-by":"crossref","unstructured":"Oriol A, Vives S, Hern\u00e1ndez-Rivas JM. Outcome after relapse of acute lymphoblastic leukemia in adult patients included in four consecutive risk-adapted trials by the PETHEMA Study Group. Haematologica. 2010; 95(4):589-596.","DOI":"10.3324\/haematol.2009.014274"},{"key":"60345","doi-asserted-by":"crossref","unstructured":"Tavernier E, Boiron JM, Huguet F. Outcome of treatment after first relapse in adults with acute lymphoblastic leukemia initially treated by the LALA-94 trial. Leukemia. 2007; 21(9):1907-1914.","DOI":"10.1038\/sj.leu.2404824"},{"key":"60346","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Stanze D, Beck J. Outcome of relapsed adult lymphoblastic leukemia depends on response to salvage chemotherapy, prognostic factors, and performance of stem cell transplantation. Blood. 2012; 120(10):2032-2041.","DOI":"10.1182\/blood-2011-12-399287"},{"key":"60347","doi-asserted-by":"crossref","unstructured":"Specchia G, Pastore D, Carluccio P. FLAG-IDA in the treatment of refractory\/relapsed adult acute lymphoblastic leukemia. Ann Hematol. 2005; 84(12):792-795.","DOI":"10.1007\/s00277-005-1090-9"},{"key":"60348","doi-asserted-by":"crossref","unstructured":"O\u2019Brien S, Schiller G, Lister J. High-dose vincristine sulfate liposome injection for advanced, relapsed, and refractory adult Philadelphia chromosome negative acute lymphoblastic leukemia. J Clin Oncol. 2013; 31(6):676-683.","DOI":"10.1200\/JCO.2012.46.2309"},{"key":"60349","doi-asserted-by":"crossref","unstructured":"Kantarjian H, Stein A, Gokbuget N. Blinatumomab versus chemotherapy for advanced acute lymphoblastic leukemia. N Engl J Med. 2017; 376(9):836-847.","DOI":"10.1056\/NEJMoa1609783"},{"key":"60350","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard therapy for acute lymphoblastic leukemia. N Engl J Med. 2016; 375(9):740-753.","DOI":"10.1056\/NEJMoa1509277"},{"key":"60351","doi-asserted-by":"crossref","unstructured":"DiJoseph JF, Armellino DC, Boghaert ER. Antibody-targeted chemotherapy with CMC-544: a CD22-targeted immunoconjugate of calicheamicin for the treatment of B-lymphoid malignancies. Blood. 2004; 103(5):1807-1814.","DOI":"10.1182\/blood-2003-07-2466"},{"key":"60352","doi-asserted-by":"crossref","unstructured":"Shor B, Gerber HP, Sapra P. Preclinical and clinical development of Inotuzumab-ozogamicin in hematological malignancies. Mol Immunol. 2015; 67(2 Pt A):107-116.","DOI":"10.1016\/j.molimm.2014.09.014"},{"key":"60353","doi-asserted-by":"crossref","unstructured":"Mohty M, Malard F, Abecassis M. Sinusoidal obstruction syndrome\/veno-occlusive disease: current situation and perspectives-a position statement from the European Society for Blood and Marrow Transplantation (EBMT). Bone Marrow Transplant. 2015; 50(6):781-789.","DOI":"10.1038\/bmt.2015.52"},{"key":"60354","doi-asserted-by":"crossref","unstructured":"Kebriaei P, Cutler C, de Lima M. Management of important adverse events associated with inotuzumab ozogamicin: expert panel review. Bone Marrow Transplant. 2018; 53(4):449-456.","DOI":"10.1038\/s41409-017-0019-y"},{"key":"60355","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Advani AS. Hepatic adverse event profile of inotuzumab ozogamicin in adult patients with relapsed or refractory acute lymphoblastic leukaemia: results from the open-label, randomised, phase 3 INO-VATE study. Lancet Haematol. 2017; 4(8):e387-e398.","DOI":"10.1016\/S2352-3026(17)30103-5"},{"key":"60356","unstructured":"Mitelman F. ISCN: an International System for human cytogenetic nomenclature. S. 1995."},{"key":"60357","doi-asserted-by":"crossref","unstructured":"Schemper M, Smith TL. A note on quantifying follow-up in studies of failure time. Control Clin Trials. 1996; 17(4):343-346.","DOI":"10.1016\/0197-2456(96)00075-X"},{"key":"60358","doi-asserted-by":"crossref","unstructured":"Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958; 53(282):457-481.","DOI":"10.1080\/01621459.1958.10501452"},{"key":"60359","doi-asserted-by":"crossref","unstructured":"Gray RJ. A class of k-sample tests for comparing the cumulative incidence of a competing risk. Ann Stat. 1988; 16(3):1141-1154.","DOI":"10.1214\/aos\/1176350951"},{"key":"60360","doi-asserted-by":"crossref","unstructured":"Harrell FE. Regression modeling strategies: with applications to linear models, logistic regression, and survival analysis. 2001.","DOI":"10.1007\/978-1-4757-3462-1"},{"key":"60361","unstructured":"R Development Core Team. R: a language and environment for statisticalaa computing. 2022. Publisher Full Text|"},{"key":"60362","doi-asserted-by":"crossref","unstructured":"Bassan R, Spinelli O, Oldani E. Improved risk classification for risk-specific therapy based on the molecular study of minimal residual disease (MRD) in adult acute lymphoblastic leukemia (ALL). Blood. 2009; 113(18):4153-4162.","DOI":"10.1182\/blood-2008-11-185132"},{"key":"60363","doi-asserted-by":"crossref","unstructured":"Johnson DB, Savani BN. How can we reduce hepatic venoocclusive disease-related deaths after allogeneic stem cell transplantation?. Exp Hematol. 2012; 40(7):513-517.","DOI":"10.1016\/j.exphem.2012.04.004"},{"key":"60364","doi-asserted-by":"crossref","unstructured":"Coppell JA, Richardson PG, Soiffer R. Hepatic venoocclusive disease following stem cell transplantation: incidence, clinical course, and outcome. Biol Blood Marrow Transplant. 2010; 16(2):157-168.","DOI":"10.1016\/j.bbmt.2009.08.024"},{"key":"60365","doi-asserted-by":"crossref","unstructured":"Marks DI, Kebriaei P, Stelljes M. Outcomes of allogeneic stem cell transplantation after inotuzumab ozogamicin treatment for relapsed or refractory acute lymphoblastic leukemia. Biol Blood Marrow Transplant. 2019; 25(9):1720-1729.","DOI":"10.1016\/j.bbmt.2019.04.020"},{"key":"60366","doi-asserted-by":"crossref","unstructured":"Giglio F, Xue E, Greco R. Defibrotide prophylaxis of sinusoidal obstruction syndrome in adults treated with inotuzumab ozogamicin prior to hematopoietic stem cell transplantation. Front Oncol. 2022; 12:933317.","DOI":"10.3389\/fonc.2022.933317"},{"key":"60367","doi-asserted-by":"crossref","unstructured":"Corbacioglu S, Cesaro S, Faraci M. Defibrotide for prophylaxis of hepatic veno-occlusive disease in paediatric haemopoietic stem-cell transplantation: an open-label, phase 3, randomised controlled trial. Lancet. 2012; 379(9823):1301-1309.","DOI":"10.1016\/S0140-6736(11)61938-7"},{"key":"60368","doi-asserted-by":"crossref","unstructured":"Cheuk DK, Chiang AK, Ha SY, Chan GC. Interventions for prophylaxis of hepatic veno-occlusive disease in people undergoing haematopoietic stem cell transplantation. Cochrane Database Syst Rev. 2015; 5:CD009311.","DOI":"10.1002\/14651858.CD009311.pub2"},{"key":"60369","doi-asserted-by":"crossref","unstructured":"Kantarjian HM, DeAngelo DJ, Stelljes M. Inotuzumab ozogamicin versus standard of care in relapsed or refractory acute lymphoblastic leukemia: final report and long-term survival follow-up from the randomized, phase 3 INO-VATE study. Cancer. 2019; 125(14):2474-2487.","DOI":"10.1002\/cncr.32116"},{"key":"60370","doi-asserted-by":"crossref","unstructured":"Badar T, Szabo A, Wadleigh M. Real-world outcomes of adult B-cell acute lymphocytic leukemia patients treated with inotuzumab ozogamicin. Clin Lymphoma Myeloma Leuk. 2020; 20(8):556-560.","DOI":"10.1016\/j.clml.2020.03.004"},{"key":"60371","doi-asserted-by":"crossref","unstructured":"Fracchiolla NS, Scium\u00e8 M, Papayannidis C. Blinatumomab and inotuzumab ozogamicin sequential use for the treatment of relapsed\/refractory acute lymphoblastic leukemia: a real-life campus All study. Cancers (Basel). 2023; 15(18):4623.","DOI":"10.3390\/cancers15184623"},{"key":"60372","doi-asserted-by":"crossref","unstructured":"G\u00f6kbuget N, Zugmaier G, Dombret H. Curative outcomes following blinatumomab in adults with minimal residual disease B-cell precursor acute lymphoblastic leukemia. Leuk Lymphoma. 2020; 61(11):2665-2673.","DOI":"10.1080\/10428194.2020.1780583"},{"key":"60373","doi-asserted-by":"crossref","unstructured":"Mohty M, Malard F, Alaskar AS. Diagnosis and severity criteria for sinusoidal obstruction syndrome\/veno-occlusive disease in adult patients: a refined classification from the European society for blood and marrow transplantation (EBMT). Bone Marrow Transplant. 2023; 58(7):749-754.","DOI":"10.1038\/s41409-023-01992-8"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284310\/76387","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.284310\/76932","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11375\/76387","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:05:23Z","timestamp":1794045923000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.284310"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,12,7]]},"references-count":38,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.284310","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,12,7]]}}}